A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients
Status:
Completed
Trial end date:
2018-08-27
Target enrollment:
Participant gender:
Summary
A multicenter, randomized, double-blinded, placebo-controlled study of two dosing frequencies
of recombinant Interleukin-7 (CYT107) treatment to restore absolute lymphocyte counts in
sepsis patients; IRIS-7B (Immune Reconstitution of Immunosuppressed Sepsis patients).
A parallel study will be performed in France to allow a common statistical analysis of the
primary end points and analysis for the enrolled patient population.
Phase:
Phase 2
Details
Lead Sponsor:
Revimmune
Collaborators:
Vanderbilt University School of Medicine Washington University School of Medicine